BT sector revenues cross $4 b

Vaccines, diagnostics and devices and personalised medicine are key innovative growth areas for domestic biotech sector, says the E&Y report titled ‘Beyond borders: Global biotechnology report - 2011.

It notes that though the year R&D funding increasingly become scarce for vast majority of firms globally. “While biotech industry’s aggregate performance improved in 2010, there is widening gap between large, established companies and those at earlier stage for whom access to capital continues to be difficult,” Ernst & Young India Partner for Life Sciences Practise Ajit Mahadevan said.

DH Newsletter Privacy Policy Get the top news in your inbox
GET IT
Comments (+)